Coronary Plaque

An artificial intelligence-derived marker using electronic health records noninvasively quantified plaque burden and mortality risk for adults from two large biobank cohorts, offering an option for more targeted CAD diagnosis, data show.

The level of total cholesterol minus HDL and LDL was associated with progression of atherosclerosis, independently of traditional CV risk factors, according to data published in Circulation: Cardiovascular Imaging.

Among adults without established CVD, a systolic BP of 118 mm Hg or less maintained over time can attenuate coronary atherosclerosis progression, according to an analysis using coronary CT angiography.

Effects of alirocumab (Praluent, Sanofi/Regeneron) on coronary atherosclerosis in patients with acute MI undergoing PCI.

WASHINGTON — In a new study, subcutaneous biweekly alirocumab, added to high-intensity statin therapy, resulted in greater coronary plaque regression in non-infarct-related arteries after 1 year in patients with acute MI.

A new study highlights an independent association between obstructive sleep apnea and coronary plaque presence and burden, suggesting it may be a risk factor for coronary events.

Although various studies have established the prognostic value of coronary artery calcium scoring for predicting atherosclerotic risk, some current models do not take coronary calcium into account, a speaker reported.

Among patients with nonflow-limiting vulnerable plaques, PCI with a bioresorbable vascular scaffold was safe and was linked to favorable long-term outcomes, according to the pilot PROSPECT ABSORB trial presented at the virtual TCT Connect.

Coronary artery plaque lipid-rich necrotic core was associated with psoriasis severity and may be improved with biologic therapy, researchers reported.

Icosapent ethyl as an adjunct to statin therapy significantly reduced multiple plaque components, including low-attenuation plaque, at 18 months, compared with placebo, according to final results of the EVAPORATE trial.